Materials And Products Tenders

Medicines with the Active Ingredient Guselkumab (Atc: L04ac16)

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Pegvisomant, Atc H01ax01 (Obo) for the Period August 1St, 2024 - July 31St, 2026

Market Research at Railway Companies (Evu) to further Develop Vehicle Financing Models

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Fesoterodine, Atc G04bd11 (Obg) for the Period August 1St, 2024 - July 31St, 2026

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Omalizumab, Atc R03dx05 (Obo) for the Period August 1St, 2024 - July 31St, 2025 (Plus Extension Option 1X12 Months)

Drywall Ba1

Drug Contracts with Accession Option

Dbs on the Receipt of Training and Education Services of Category 3

Dbs on the Receipt of Training and Education Services of Category 4

Dbs on the Receipt of Training and Education Services of Category 7